관절내 점성보충 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Viscosupplementation Market size is expected to reach USD 15.72 Billion in 2034 from USD 6.62 Billion (2025) growing at a CAGR of 10.09% during 2026-2034.

The global viscosupplementation market has grown steadily as osteoarthritis becomes more prevalent, particularly among aging populations. Viscosupplementation involves injecting hyaluronic acid into joints, especially the knee, to improve lubrication and reduce pain. This treatment option is widely used when conventional therapies such as pain medication or physical therapy provide limited relief. Increasing awareness about minimally invasive treatments and the need for effective joint pain management has contributed to the expansion of this market.

The market is driven by several important factors, including the rising global burden of osteoarthritis and joint disorders. Aging demographics and increasing rates of obesity have led to greater demand for joint treatment solutions. Patients and healthcare providers are increasingly choosing viscosupplementation as a non-surgical alternative for managing joint pain. Improvements in hyaluronic acid formulations and longer-lasting injections have also enhanced treatment effectiveness and patient satisfaction.

In the coming years, the viscosupplementation market is expected to benefit from continued advancements in orthopedic therapies. Research efforts focused on improving injection formulations and extending treatment duration may enhance clinical outcomes. Expanding healthcare access and increasing awareness about joint preservation therapies will likely drive adoption. As patients seek less invasive methods to manage joint pain and maintain mobility, viscosupplementation is expected to remain an important therapeutic option.

MARKET SEGMENTATION

By Product

• Single Injection
• Three Injection
• Five Injection

By End Use

• Hospitals
• Orthopedic Clinics/ASCs

COMPANIES PROFILED

• DePuy Synthes, Fidia Farmaceutici SpA, Sanofi, Smith Nephew plc, Anika Therapeutics Inc, Seikagaku Corporation, Zimmer Biomet Holdings Inc, Ferring Pharmaceuticals BV, Lifecore Biomedical LLC, LG Life Sciences Ltd, F HoffmannLa Roche Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VISCOSUPPLEMENTATION MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Single Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Three Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Five Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VISCOSUPPLEMENTATION MARKET: BY END USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End Use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Orthopedic Clinics/ASCs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VISCOSUPPLEMENTATION MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By End Use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By End Use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By End Use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By End Use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By End Use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL VISCOSUPPLEMENTATION INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 DePuy Synthes
  • 8.2.2 Fidia Farmaceutici S.p.A
  • 8.2.3 Sanofi
  • 8.2.4 Smith & Nephew Plc
  • 8.2.5 Anika Therapeutics Inc
  • 8.2.6 Seikagaku Corporation
  • 8.2.7 Zimmer Biomet Holdings Inc
  • 8.2.8 Ferring Pharmaceuticals B.V
  • 8.2.9 Lifecore Biomedical LLC
  • 8.2.10 LG Life Sciences Ltd
  • 8.2.11 F. Hoffmann-La Roche Ltd